Related Experiment Video
Updated: Feb 25, 2026
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
New treatment options for metastatic renal cell carcinoma
Alejo Rodriguez-Vida1, Thomas E Hutson2, Joaquim Bellmunt1
1Medical Oncology Department, Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain.
Abstract:
During the last decade, the treatment of advanced or metastatic renal cell carcinoma (RCC) was revolutionised with the advent of antiangiogenic drugs and tyrosine-kinase inhibitors. Several agents targeting the vascular endothelial growth factor (VEGF) pathway (sunitinib, bevacizumab, pazopanib, axitinib) or the mammalian target of rapamycin pathway (temsirolimus, everolimus) were since then progressively approved for first-line or later-line use in the treatment of patients with advanced RCC and became the new standard of care. As a result, the survival of patients with advanced RCC has significantly improved from a median overall survival of approximately 12 months in the cytokines era to more than 26 months with first-line VEGF inhibitors. During the two last years, the treatment of advanced RCC has witnessed a second revolution with the advent of immune checkpoint inhibitors, especially agents targeting the programmed cell death-1 receptor, as well as with the advent of new generation tyrosine-kinase receptor inhibitors. This article will review the new therapeutic options available for the treatment of advanced RCC, as well as the future potential molecular targets that are currently being investigated.
Insights
Advanced renal cell carcinoma (RCC) treatment has advanced significantly. New therapies, including antiangiogenic drugs and immune checkpoint inhibitors, have improved patient survival, offering new hope for advanced RCC.
Area of Science:
- Oncology
- Medical Research
Background:
- The last decade saw a revolution in advanced renal cell carcinoma (RCC) treatment with antiangiogenic drugs and tyrosine-kinase inhibitors.
- Agents targeting the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways became the standard of care.
- Significant survival improvements were observed, increasing median overall survival from 12 to over 26 months.
Purpose of the Study:
- To review recent therapeutic advancements in advanced RCC.
- To discuss emerging immune checkpoint inhibitors and new-generation tyrosine-kinase inhibitors.
- To explore potential future molecular targets in advanced RCC treatment.
Main Methods:
- Review of current literature on advanced renal cell carcinoma therapies.
- Analysis of clinical trial data for approved and investigational agents.
- Discussion of emerging treatment paradigms and future research directions.
Main Results:
- Antiangiogenic drugs and tyrosine-kinase inhibitors have significantly improved survival in advanced RCC.
- Immune checkpoint inhibitors represent a second revolution in advanced RCC treatment.
- New generation tyrosine-kinase inhibitors offer further therapeutic options.
Conclusions:
- The treatment landscape for advanced RCC has been transformed by targeted therapies and immunotherapy.
- Continued research into novel molecular targets is crucial for further improving patient outcomes.
- Current therapeutic options offer significantly better survival rates compared to previous treatment eras.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:28Chronic Kidney Disease III: Interprofessional Care
01:30Urinary Tract Calculi III: Medical Management
01:27Tumor Immunotherapy
01:25Urinary Tract Calculi VI: Surgical Management
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...